UNIVERSITY OF WASHINGTON
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Private
- Established
- 1861-01-01
- Employees
- 10K
- Market Cap
- -
Herpes Simplex Virus Type 2 (HSV-2) Suppression to Prevent HIV Transmission
Phase 3
Completed
- Conditions
- HIV InfectionHerpes Simplex, GenitalSexually Transmitted Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 3408
- Registration Number
- NCT00194519
- Locations
- πΊπ¬
Mulago Hospital - IDI, Kampala, Uganda
π·πΌProjet San Francisco-Emory University, Kigali, Rwanda
π°πͺUniversity of Nairobi, Nairobi, Kenya
Cerebral Perfusion Pressure (CPP) Management Information Feedback and Nursing
Not Applicable
Completed
- Conditions
- Traumatic Brain InjurySubarachnoid Hemorrhage
- Interventions
- Other: Bedside display of cerebral perfusion pressure information
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 260
- Registration Number
- NCT00194441
- Locations
- πΊπΈ
University of Washington, Seattle, Washington, United States
Cefpodoxime vs Ciprofloxacin for Acute Cystitis
Not Applicable
Completed
- Conditions
- Urinary Tract Infection
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2014-06-10
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 300
- Registration Number
- NCT00194532
- Locations
- πΊπΈ
University of Miami Miller School of Medicine, Miami, Florida, United States
πΊπΈUniversity of Washington, Seattle, Washington, United States
Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer
Phase 2
Terminated
- Conditions
- Estrogen Receptor-positive Breast CancerStage IIIA Breast CancerHER2-negative Breast CancerProgesterone Receptor-positive Breast CancerStage I Breast CancerStage II Breast Cancer
- Interventions
- Procedure: therapeutic conventional surgeryRadiation: radiation therapyOther: laboratory biomarker analysis
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 28
- Registration Number
- NCT00194792
- Locations
- πΊπΈ
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Preferred Treatment of Type 1.5 Diabetes
Not Applicable
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 64
- Registration Number
- NCT00194896
- Locations
- πΊπΈ
DVA Puget Sound Health Care System, Seattle, Washington, United States
Effect of Medication Diaries on Adherence to Highly Active Antiretroviral Drugs Among HIV-1 Infected Kenyan Children
Phase 2
Completed
- Conditions
- HIV Infections
- Interventions
- Behavioral: Medication diaries
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-07-09
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 100
- Registration Number
- NCT00194545
- Locations
- π°πͺ
University of Nairobi, Nairobi, Kenya
Botox as a Treatment for Interstitial Cystitis in Women
Phase 4
Completed
- Conditions
- Painful Bladder SyndromeInterstitial Cystitis
- Interventions
- Other: normal saline
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-10-12
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 20
- Registration Number
- NCT00194610
Effectiveness of Sympathetic Plexus Block on Male Pelvic Pain (Prostatitis, Prostatodynia)
Phase 4
Suspended
- Conditions
- ProstatitisChronic Male Pelvic Pain Syndrome
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 20
- Registration Number
- NCT00194636
- Locations
- πΊπΈ
University of Washington - Urology Clinic, Seattle, Washington, United States
Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-09-13
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 40
- Registration Number
- NCT00194727
- Locations
- πΊπΈ
University of Washington; Seattle Cancer Care Alliance, Seattle, Washington, United States
Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12
Phase 2
Completed
- Conditions
- Breast Neoplasm
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-09-13
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 80
- Registration Number
- NCT00194753
- Locations
- πΊπΈ
University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States
Β© Copyright 2025. All Rights Reserved by MedPath